Original paper
P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
Abstract
The KEAP1/NRF2 pathway is mutationally activated in approximately 20-25% of NSCLC patients. NRF2 activation protects against oxidative stress and promotes tumor growth and survival. KEAP1/NRF2 mutations in advanced NSCLC are associated w/ dramatically shorter survival and poor outcomes following standard-of-care therapy. These tumors have heightened dependency on glutaminase-mediated conversion of glutamine to glutamate due to upregulation of...
Paper Details
Title
P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
Published Date
Oct 1, 2021
Journal
Volume
16
Issue
10
Pages
S1099 - S1099
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History